



US009636406B2

(12) **United States Patent**
Bender(10) **Patent No.:** US 9,636,406 B2
(45) **Date of Patent:** *May 2, 2017(54) **METHOD OF TREATING CANCER**(71) Applicant: **Intensity Therapeutics, Inc.**, Westport, CT (US)(72) Inventor: **Lewis H. Bender**, Redding, CT (US)(73) Assignee: **Intensity Therapeutics, Inc.**, Westport, CT (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/052,326**(22) Filed: **Feb. 24, 2016**(65) **Prior Publication Data**

US 2016/0166697 A1 Jun. 16, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/280,036, filed on May 16, 2014, now Pat. No. 9,351,997, which is a continuation of application No. PCT/US2013/059841, filed on Sep. 15, 2013.

(60) Provisional application No. 61/779,509, filed on Mar. 13, 2013, provisional application No. 61/707,733, filed on Sep. 28, 2012, provisional application No. 61/703,890, filed on Sep. 21, 2012.

(51) **Int. Cl.**

A61K 47/12 (2006.01)
A61K 47/18 (2017.01)
A61K 9/08 (2006.01)
A61K 9/00 (2006.01)
A61K 45/06 (2006.01)
A61K 31/475 (2006.01)
A61K 31/7105 (2006.01)
A61K 31/282 (2006.01)
A61K 31/7032 (2006.01)
A61K 31/192 (2006.01)
A61K 31/20 (2006.01)
A61K 31/216 (2006.01)
A61K 31/555 (2006.01)
A61K 33/24 (2006.01)
A61K 47/14 (2017.01)

(52) **U.S. Cl.**

CPC *A61K 47/12* (2013.01); *A61K 9/006* (2013.01); *A61K 9/08* (2013.01); *A61K 31/192* (2013.01); *A61K 31/20* (2013.01); *A61K 31/216* (2013.01); *A61K 31/282* (2013.01); *A61K 31/475* (2013.01); *A61K 31/7032* (2013.01); *A61K 31/7105* (2013.01); *A61K 33/24* (2013.01); *A61K 45/06* (2013.01); *A61K 47/14* (2013.01); *A61K 47/18* (2013.01); *A61K 9/0019* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,679,638 A 10/1997 Teicher et al.
5,866,536 A 2/1999 Leone-Bay et al.
5,874,402 A 2/1999 Singh et al.
6,110,492 A 8/2000 Alving et al.
7,648,695 B2 1/2010 Dees et al.
9,351,997 B2 5/2016 Bender
2008/0167217 A1 7/2008 Rath et al.
2009/0123562 A1 5/2009 Bender et al.
2009/0143330 A1 6/2009 Levchik et al.
2009/0186802 A1 7/2009 Alluis et al.
2011/0300223 A1 12/2011 Nishio et al.
2013/0156859 A1 6/2013 Koshi et al.

FOREIGN PATENT DOCUMENTS

WO WO 01/34130 5/2001
WO WO 03/007869 1/2003
WO WO 2004/081196 9/2004
WO WO 2005/107462 11/2005
WO WO 2006/072070 7/2006
WO WO 2008/095144 7/2008
WO WO 2011/084061 7/2011
WO WO 2011/112889 9/2011

(Continued)

OTHER PUBLICATIONS

Li, X. et al., "Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate," European Journal of Pharmaceutics and Biopharmaceutics 70 (2008) 726-734.*

Supplementary European Search Report for European Application No. 13838639.6, mailed Apr. 1, 2016, 11 pages.

International Search Report and Written Opinion for International Application No. PCT/US2013/059841, mailed Dec. 17, 2013, 8 pages.

Ajima, K. et al., "Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohoms," ACS Nano., 2(10):2057-2064 (Oct. 2008).

American Cancer Society, "Filgrastim," WayBack Macine [Online], <http://www.cancer.org/Treatment/TreatmentsandSideEffects/GuidetoCancerDrugs/filgrastim>, Mar. 28, 2011, 3 pages.

(Continued)

Primary Examiner — Tracy Vivlemore

Assistant Examiner — Monica Shin

(74) *Attorney, Agent, or Firm* — Cooley LLP; Ivor R. Elrifi; Matthew Pavao

(57) **ABSTRACT**

The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.